You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
SBC: VERRA THERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy
SBC: Advanced Gene Transfer Company, Inc. Topic: 105ABSTRACT The HIV pandemic has caused an estimated 33 million deaths to date. In the U.S. alone, 1.2 million people currently live with HIV and 34,800 new cases were diagnosed in 2019. This adds up to an estimated $16.4 billion for a lifetime of HIV treatment for patients in the U.S. HIV infects immune cells which express the CD4 and CXCR4/CCR5 co-receptors including helper T-cells. Even after a pa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms
SBC: NEUROVASCULAR DIAGNOSTICS, INC. Topic: 103Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Non-Clinical Pharmacology of CX-01
SBC: Ceramedix Holding, LLC Topic: NIAIDDevelopment of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies
SBC: Akeso Therapeutics Inc Topic: 102PROJECT SUMMARY/ABSTRACTThe major hurdle in developing chimeric antigen receptor (CAR)-T therapy for T-cell malignancies is CAR-T cell fratricide by self-killing, which leads to insufficient numbers of CAR-T cells for infusion. CRISPR- mediated genomic editing provides an alternative approach to enabling expansion of CAR transduced T cells from allogeneic healthy donors. However, the safety and cl ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism
SBC: Cytodel, Inc. Topic: 107Abstract Botulinum neurotoxin serotype A1 (BoNT/A1) has become an important therapeutic tool for multiple indications, despite being the most toxic protein known to science. Although serious Adverse Events (AEs) are rare, their importance is recognized by the Black Box warning included in the labeling for all FDA-approved BoNT/A1 products. During a recent 3-year period FDA received 13,087 AE repor ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
SBC: VITAN-BIOTECH LLC Topic: 300Project SummaryA broad range of neurological indications, including schizophrenia, pain, Parkinson's and Alzheimer's diseases, and autism have been linked to G-protein coupled receptor proteins (GPCRs), making them attractive targets for therapy. Understanding GPCR dysfunction is essential for effective therapeutic development. However, deciphering the functions of GPCRs remains a daunting task in ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Pediatric Airway Trainer for Enhanced Clinical Education in Pediatric Critical Care
SBC: TDA RESEARCH, INC. Topic: NICHDProject Summary/Abstract Clinical training aids such as surgical mannequins and procedural trainers are important tools for teaching proper technique to physicians and first responders. However, the majority of these training tools were developed for adult anatomies. Pediatric patients are often more challenging to treat, but few resources exist for advanced simulation in pediatric critical care e ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating
SBC: Halomine Inc. Topic: NIAIDProject Summary/Abstract In the US, about 1.7 million Healthcare-Associated Infections (HAls) occur in hospitals each year, resulting in 99,000 deaths and an estimated $20 billion in healthcare costs. According to previous reports, as much as one third of HAI cases can be attributed to environmental surfaces, namely “high touch” surfaces (e.g., bed rails, machine buttons, equipment), in hospit ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease
SBC: Spark Neuro Inc. Topic: NIAPROJECT SUMMARY Alzheimer’s disease (AD) is a progressive, neurodegenerative condition that impacts 44 million people globally. It is the most common cause of dementia—accounting for 80% of all dementia diagnoses—and predominantly affects older people. To date, AD has no cure. Thus, it is imperative to diagnose patients as early as possible to maximize the efficacy of symptom management stra ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health